Autologous stem cell transplant plus Rituxan did not improve survival outcomes in certain patients with mantle cell lymphoma ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

A Phase 3 trial of uproleselan failed to improve overall survival in relapsed/refractory AML, though it may benefit primary ...

Gratitude is actively practiced, even amidst personal losses and living with metastatic cancer, highlighting its importance ...

In an interview with CURE ®, Maggie Bushway reflected on rediscovering her childhood writings and her father's blog posts ...

Patients with newly diagnosed multiple myeloma experienced robust clinical activity when treated with Tecvayli (teclistamab) ...

Long-term follow-data shows Revuforj to be effective in the treatment patients with R/R KMT2Ar acute leukemias.

Calquence plus Venclexta, with or without Gazyva, improved progression-free survival over the standard-of-care ...

The risk for disease progression or death was reduced by 51% with subcutaneous Darzalex Faspro in certain patients with ...

One year, after breast cancer treatment, I decided to have a Christmas photoshoot with my family, which turned out to be a good laugh in the end.

Scemblix resulted in better outcomes and fewer side effects compared to standard tyrosine kinase inhibitor therapies in ...

For patients with transplant-ineligible or -deferred newly diagnosed multiple myeloma, the addition of Darzalex to VRd ...